Skip to main content
. 2017 Nov 29;6(12):e003700. doi: 10.1161/JAHA.116.003700

Figure 2.

Figure 2

A, Average estimated galectin‐3 pattern during initial hospitalization for decompensated heart failure for patients with and without the primary end point. The figure includes the individual galectin‐3 measurements for patients with and without the primary end point. B, Average estimated galectin‐3 pattern before the primary end point or end of follow‐up for patients with and without the primary end point. The figure includes the individual galectin‐3 measurements for patients with and without the primary end point. The average estimated galectin‐3 levels are adjusted for age, sex, systolic blood pressure, diabetes mellitus, LVEF, previous hospitalization for heart failure during the past 6 months, ischemic heart failure, body mass index, eGFR, medication use at hospital discharge (ACE‐I and/or ARB, β‐blocker, and diuretics), and baseline NT‐proBNP (model 3). ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.